TECH · 10-Q/A · 2026Q3 · Full report

Pending Merger with Merck

BIO-TECHNE Corp · 2026-11-12 · Importance 71 · Surprise 60

In June 2026, Bio-Techne entered into a merger agreement with Merck KGaA, Darmstadt, Germany, under which Merck’s wholly owned subsidiary will merge into Bio-Techne, which will survive as a wholly owned subsidiary. Bio-Techne shareholders approved the agreement on September 23, 2026. The merger was expected to close by late 2026 or early 2027, subject to customary closing conditions, including regulatory approvals.

Key facts

• BIO-TECHNE shareholders approved the Merger Agreement on September 23, 2026; the merger with Merck KGaA is expected to close by late 2026 or early 2027, subject to customary closing conditions. source
• The proposed Merger is expected to close by late 2026 or early 2027, subject to additional customary closing conditions. source
• Bio-Techne shareholders voted to approve the Merger Agreement on September 23, 2026. source
• Bio-Techne faces the risk that the Merger may not be completed in a timely manner or at all, and that conditions including regulatory approvals may not be satisfied. source
• The Merger may involve unanticipated difficulties or expenditures and affect Bio-Techne’s plans, business relationships, operating results, and operations. source
• Legal proceedings may be instituted against Bio-Techne, its board, executive officers, or others following announcement of the Merger. source
• The Merger announcement and pendency may make it difficult for Bio-Techne to retain customers, suppliers, distributors, and employees, and may divert management attention from ongoing operations. source